Dergiler / GORM:Gynecology Obstetrics & Reproductive Medicine / 2018 / Cilt: 24 - Sayı: 3

Stage IB Endometrioid Type Endometrial Cancer: The Role of Lymphadenectomy and Adjuvant Radiation Therapy

Sayfa
156–161
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Lymphadenectomy had a survival benefit for patients with myometrial invasion greater than a half of myometrial thickness.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:OBJECTIVE: Both performances of lymphadenectomy and benefit of adding adjuvant radiotherapy are controversial for patients with International Federation of Gynecology and Obstetrics stage IB endometrioid type endometrial cancer.
📊
Temel Bulgular & Veri:STUDY DESIGN: Records of all patients (n=132) with stage IB endometrioid endometrial cancer who were referred to or treated in our institution between Jan 1992 and Dec 2013 were retrospectively reviewed.
💡
Sonuç & Katkı:Lymphadenectomy had a survival benefit for patients with myometrial invasion greater than a half of myometrial thickness.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:2013 Verileri
⚙️Değişkenler:Alan Parametreleri

Özet

OBJECTIVE: Both performances of lymphadenectomy and benefit of adding adjuvant radiotherapy are controversial for patients with International Federation of Gynecology and Obstetrics stage IB endometrioid type endometrial cancer. We aimed to identify the role of lymphadenectomy and adjuvant radiation therapy as well as clinicopathological prognostic factors for this group of patients. STUDY DESIGN: Records of all patients (n=132) with stage IB endometrioid endometrial cancer who were referred to or treated in our institution between Jan 1992 and Dec 2013 were retrospectively reviewed. Cox Proportional Hazard Regression Analysis was used to determine the effects of lymphadenectomy and adjuvant radiation as well as other clinicopathological factors on disease free survival and overall survival. RESULTS: Mean age was 59.9 years (range, 45-82). Lymphadenectomy didn't perform in 36 (27.3%) patients and 23 (17.4%) patients did not have any kind of adjuvant treatment. Mean lymph node count was 18.8 (range, 3-67). Federation of Gynecology and Obstetrics grade, lymphovascular space invasion, lymphadenectomy, receiving adjuvant treatment and type of received adjuvant therapy were not associated with disease free survival and overall survival for the entire cohort. In a subgroup of patients with grade1&2 tumor, 5-year disease free survival rates were 80% and 50% (p=0.4), respectively and overall survival rates were 94.8% and 93.8% (p=0.2), respectively for patients who had or didn't have adjuvant radiotherapy. While performance of lymphadenectomy was not significantly associated with disease free survival in this subgroup (p=0.56), this association was statistically significant for overall survival (97.9% vs. 86.4%, (p=0.04). CONCLUSION: Benefit of adjuvant radiotherapy in regard to prevention of recurrence needs to be confirmed by further studies. Lymphadenectomy had a survival benefit for patients with myometrial invasion greater than a half of myometrial thickness.

🔖

Bu Makaleye Atıf Yap

TURKMEN, O., TASCI, T., BASARAN, D., KIMYON, G. C., KARALOK, A., UREYEN, I., TURAN, T. A. (2018). Stage IB Endometrioid Type Endometrial Cancer: The Role of Lymphadenectomy and Adjuvant Radiation Therapy. GORM:Gynecology Obstetrics & Reproductive Medicine, Cilt: 24 - Sayı: 3, 156–161. https://ajindex.com/articles/164996

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Chan JK, Kapp DS. The role of complete lymphadenectomy in endometrioid uterine cancer. Lancet Oncol 2007; 8(9):831-41
  2. Maggino T, Romagnolo C, Landoni F, et al. An analysis of approaches to the management of endometrial cancer in North America: a CTF study. Gynecol Oncol 1998;68(3): 274-9
  3. Maggino T, Romagnolo C, Zola, et al. P. An analysis of approaches to the treatment of endometrial cancer in western Europe: a CTF study. Eur J Cancer 1995;31A(12): 1993-7
  4. Mariani A, Webb MJ, Keeney GL, et al. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol. 2000;182(6):1506-19. 5. group As, Kitchener H, Swart AM, et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomized study. Lancet 2009; 373(9658):125-36
  5. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105(2):103-4
  6. Benedetti Panici P, Basile S, Maneschi F, et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100(23):1707-16
  7. De Wilde RL, Rafei A, Herrmann A. Can a lymphadenectomy be avoided in early-stage endometrial adenocarcinoma? Arch Gynecol Obstet. 2014;290(5):973-8
  8. Koskas M, Fournier M, Luton D, et al. Survival impact of lymphadenectomy stratified by nodal metastatic probability in endometrial cancer. Ann Surg Oncol 2014;21 (7):2376-82
  9. Anderson B, Connor JP, Andrews JI, et al. Obesity and prognosis in endometrial cancer. Am J Obstet Gynecol 1996 Apr;174(4):1171-8; discussion 8-9
  10. Bogani G, Dowdy SC, Cliby WA, et al. Role of pelvic and para-aortic lymphadenectomy in endometrial cancer: current evidence. J Obstet Gynaecol Res 2014;40(2):301-11
  11. Yost KJ, Cheville AL, Al-Hilli MM, et al. Lymphedema after surgery for endometrial cancer: prevalence, risk factors, and quality of life. Obstet Gynecol 2014;124 (2 Pt 1):307-15
  12. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95 Suppl 1:S105-43
  13. Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol 2013;24 Suppl 6:vi33-8
  14. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-